


RemediumOne

FOR LIFE




YOUR PARTNER FOR LIFE

SRI LANKA


A preferred destination for clinical research


Referred to in ancient times as the Pearl of the Indian Ocean, Sri Lanka has long since been a vital hub for trade and commerce between East and West. Her cosmopolitan background and colonial history has given her a strong foundation in Roman Dutch law, the English language, and high professional standards, rendering her an ideal location to conduct medical research and clinical trials.



WHY?


Universal state funded health coverage
- zero standard of care costs to sponsor



Quick & predictable startup timeline
(12-16 weeks)


Proven track record in clinical research

Accredited laboratories
(e.g. CAP accreditation)




Excellent hospital & healthcare structure
- impressive health indices


Highly qualified medical specialists


Robust regulatory framework



Good support infrastructure
- mobile & internet connectivity, IT,
drug depots and document archival



Expanding middle-income population with high disease burden



Highly literate population - meaningful informed consenting, excellent long-term retention



Government as enabler with stable security & political environment



Geographical location - well connected to the world

COUNTRY SNAPSHOT

PER CAPITA GDP: 3836 USD

MIDDLE INCOME COUNTRY as of 2015

NATIONAL LITERACY RATE: 94.2%

POPULATION: Not genetically homogenous and stable in terms of internal migration

LIFE EXPECTANCY: Male - 74 | Female - 77

GEOGRAPHIC LOCATION: Strategically situated on the main trade routes between Asia and the Middle East

TOTAL LAND: 65,610 Sq. Km

TOTAL POPULATION: 21.3 million (Growth rate – 0.5%)

COMMERCIAL CAPITAL: Colombo

BUSINESS LANGUAGE: English

STABLE DEMOCRACY, LAW AND ORDER



ROBUST HEALTHCARE STRUCTURE



STATE-FUNDED HEALTH COVERAGE

Sri Lanka has a free and universal healthcare system. It is organized through both public and private sectors, and includes the services of those practicing within the allopathic system of health care, along with traditional medicine such as ayurvedic and homeopathic treatments.



TERTIARY CARE HOSPITALS

Large, well-equipped, tertiary-care hospitals compatible with those in developed countries with all major and sub specialties. Sector curative services are provided through a series of health care institutions ranging from basic central dispensaries to teaching hospitals and the National Hospital of Sri Lanka (NHSL).



PATIENT-RELATED DOCUMENTS

The business language utilized in Sri Lanka is English. The patient related documents are all maintained in English.



DEDICATED SPECIALTY HOSPITALS

In Sri Lanka, there are various hospitals which contain units dedicated to specialties. Many hospitals from NHSL to CSTH to Kandy Teaching Hospital contain their very own neurotrauma, cardiology, nephrology units; the National Cancer Institute (NCI) was setup for the treatment of cancer patients.



WESTERN HEALTHCARE INSTITUTIONS


Both the public and private sectors are involved in the delivery of allopathic healthcare systems, primarily governed by the Ministry of Health, which ensures provisions of comprehensive health services to all citizens.



PRIMARY HEALTHCARE STRUCTURE

Well organized primary healthcare structure that facilitates patient retention for studies with long-term follow up

Immunization cover > 98%
Death registration > 95%
MMR – 12/100,000 live births
IMR – 11.2/1000 live births



DISEASE BURDEN



Sri Lanka is witnessing a shift in the disease burden from communicable diseases to noncommunicable diseases (NCDs). 103 500 people die in Sri Lanka each year due to NCDs, which accounts for 75% of all deaths in the country. The NCD epidemic poses a serious economic issue, as a significant proportion of the annual health budget is spent on NCD treatment. NCD prevention and control measures are a key priority for the government' (World Health Organisation, 2016)



TROPICAL/INFECTIOUS DISEASES

In 2017, 184442 suspected dengue cases were reported island-wide to the Epidemiology Unit

41.53% of the dengue cases were reported from the Western province
No. of cases of Rabies in Sri Lanka from 2000-2016

To overcome NTDs in 2012, World Health Organisation (WHO) published a strategic plan which included the eradication of the tropical diseases



NON COMMUNICABLE DISEASES


Non communicable diseases (NCDs) now account for approximately 85% of the disease burden

Burden due to NCDs is equal to that of high income countries

NCD Burden: the urban-rural divide is narrowing

Prevalence of major NCD risk factors is expected to increase

A SHIFT IN DISEASE BURDEN IS TAKING PLACE



PREVALENCE OF NCDs IN SRI LANKA

- Cancer: 1.7%
- Heart disease: 9.0%
- Diabetes: 30.4%
- Hypertension: 39.0%
- Epilepsy: 1.7%

(Ministry of National Policies and Economic Affairs, 2014)

QUALIFIED MEDICAL SPECIALISTS



Medical doctors produced exclusively by State Universities



Most specialist doctors - in all major and sub-specialties - highly trained and possess overseas postgraduate degrees



Local postgraduate medical degrees recognized by the GMC, UK




Culture of conducting and participating in clinical trials



Mandatory overseas training at centres of excellence (usually in the UK & Australia) for board-certification as specialists



Prior clinical trials experience in conducting multicenter multinational studies



WELL DEFINED REGULATORY REQUIREMENT

WHO ARE WE?

Our journey started at the University of Kelaniya with a few investigator initiative studies. In 2009, we evolved to become an officially established clinical research management organisation. The number of employees has now grown to 86 employees working across over 50 sites around the country.





Health and medical research and its translation into evidence-based clinical practice, public health policy and health services delivery are vital for the continued advancement of human health and wellbeing. As Sri Lanka's pioneering clinical trials management company, RemediumOne plays a critical role in supporting the broad range of research activities needed to address current and future health challenges in partnership with key stakeholders in the country and collaborators around the world.

Sri Lanka's clinical research environment like any other market is expected to change dramatically over the coming years, but our overriding philosophy of placing clients and quality at the heart of everything we do will remain unchanged. As we head towards 2019, our 10th anniversary and beyond, we will continue to transform ourselves and take on new challenges with the aim of creating a solid operating platform that can deliver consistent results under any circumstance.

As an innovation-led organization focused on providing high-quality clinical trial management services, we have leveraged our inherent strengths in project coordination and implementation with those of our academic partner to successfully conduct a diverse portfolio of hospital- and community-based clinical research projects. The desire for excellence of our staff at RemediumOne who have never been afraid of change or taking on new challenges is at the heart of our success. We believe our human capital input makes the biggest difference in delivering excellent results consistently across projects in varied therapeutic areas.

Looking ahead, we are entering an era in which conventional wisdom will be increasingly challenged and the healthcare industry will also see considerable changes. No matter what the future holds, RemediumOne will expand our focus with an eye on helping solve the issues of our research partners and continue to be relevant to society.

Samantha Ranatunga
CEO/ Director

Board of Directors



KARTHI GAJENDRAN | CHAIRMAN

Mr Gajendran, a British and Sri Lankan citizen, brings over 33 years of international experience in Strategy, advocacy, leadership, operations and governance in industries ranging from airports and aviation, infrastructure, marketing communication, healthcare, hospitality and civic services.

From 2010 to 2020, Mr. Gajendran, Airport Development for GVK Group, one of the largest private airport operators in Asia. In addition to overseeing the multibillion-dollar development of airports in India, he is responsible for GVK's international strategy and investments and the operations in Indonesia managing the redevelopment of Ngurah Rai International Airport in Bali, and construction of a new green field airport in Yogyakarta, Indonesia.

Prior to joining GVK in 2010, he was a Senior Vice President at CH2M HILL, a Fortune 500, global leader in full-service engineering, construction, procurement and program management firm. Based in London, he spent 10 years as the Commercial & Operations Director for Europe & Middle East operations and also served as a Board Director for a number of CH2M HILL's subsidiaries. Under Mr Gajendran's leadership, both Mumbai and Bali International Airports became world's number one airport in their class, as ranked by Airport Council International, the apex body of international airports.

He has also worked at WPP Group PLC, the global leader in marketing services and their subsidiary Hill & Knowlton as the Chief Financial Officer for Central & Eastern European operations in London and Brussels for almost 10 years. He holds a post graduate certificate in economics from Birkbeck College, University of London and is a Fellow Chartered Management Accountant (FCMA), United Kingdom.



SAMANTHA RANATUNGA | CEO, DIRECTOR

Mr. Samantha Ranatunga has a wealth of experience in a variety of industries. He also held the position as Chairman of the Ceylon Chamber of Commerce. Mr. Ranatunga has worked for 30 years at the CIC Group and of it 10 years as its Managing Director and CEO. Mr. Ranatunga also served as an independent director at the Seylan Bank Board for 9 years.

His desire to reconnect with the field of science and technology aided his decision to join a center of scientific excellence such as RemediumOne. Using his experience as a pioneer in coordinating and setting up agricultural and pharmaceutical businesses of CIC, Mr. Ranatunga will help our quest to strategically build and position RemediumOne in the global clinical trial industry to create further business opportunities for the organization and its potential stakeholders.

Board of Directors



PRIYANGA GUNASEKERA | DIRECTOR

Priyanga Gunasekera has almost twenty years of experience in all aspects of sales and marketing and business management in Information Technology. He has a BSc (Hon) degree in Computer Science from University of Colombo and since been involved in the IT sector at various levels.

After starting his career as a Systems Engineers, he rose to be a Director of Informatics (Pvt) Ltd., a position that he held until March 31, 2011. Currently he is the Managing Director of V S information Systems (Pvt) Ltd. a leading Information Technology company in Sri Lanka.

During his career, he has held positions in several industry organisations such as the Sri Lanka Computer Vendors Association, (SLCVA) and Sri Lanka Association of Software and Service Companies (SLASSCOM) and was the Chairman of the IT Sector of the National Chamber of Commerce of Sri Lanka (NCCSL) from 2008 to 2010.



SALIYA WICKRAMASURIYA | DIRECTOR

Saliya Wickramasuriya joined the upstream oil and gas industry in 1984, working for Schlumberger, the world's largest petroleum services company. Following 20 years in oil exploration worldwide, he returned to Sri Lanka in 2004, where he was appointed Chairman/Director General of the Sri Lanka Board of Investment.

Thereafter, he was appointed Chairman of the Sri Lanka Ports Authority, in which capacity he negotiated and commenced the Colombo Port Expansion and Hambantota Port Phase I projects. He retired from Government service in June 2017 after spending the previous 6 years as the Director General of the Petroleum Resources Development Secretariat, an institution tasked with developing the country's emerging upstream petroleum industry.

Mr. Wickramasuriya is currently Co-Chair of the National Agenda Committee on Energy of the Ceylon Chamber of Commerce, and a consultant to the Ministry of Energy. In these capacities he is assisting the Minister of Energy in his initiative to introduce policy targeting net-zero carbon emission for Sri Lanka by 2050. Mr Wickramasuriya is also in the newly formed Colombo Port City Economic Commission, where he serves as Acting Director General in addition to his role as Commission Member.

A wealth of advice at our disposal.



PROFESSOR DAVID LALOO

Professor of Medicine,
Dean of Clinical Sciences and International Public Health,
Liverpool School of Tropical Medicine,
United Kingdom



PROFESSOR JANE ARMITAGE

Professor of Clinical Trials and Epidemiology,
& Honorary Consultant in Public Health
Medicine, University of Oxford,
United Kingdom



PROFESSOR ANUSHKA PATEL

Chief Scientist, The George Institute for Global Health,
Professor of Medicine, UNSW Sydney,
Cardiologist, Royal Prince Alfred Hospital,
Australia

RemediumOne

FOR LIFE

FOUNDED IN

2009

in partnership with
the Faculty of Medicine,
University of Kelaniya



86

FULLTIME
PROFESSIONALS
on staff

300+

INVESTIGATORS
presently engaged
in active projects



RemediumOne
PIONEERING
CLINICAL RESEARCH
in Sri Lanka



COLLABORATION

with the world's leading
Centers of Excellence:

- Clinical Trials Unit, University of Oxford
- Duke Clinical Research Institute
- The George Institute for Global Health
- University of Nottingham
- Duke-NUS Graduate Medical School
- National Cancer Centre, Singapore



ISO 9001:2015

CERTIFIED CLINICAL TRIALS
management service provider

ISO 27001:2013

INFORMATION SECURITY
MANAGEMENT SYSTEM



Vision

OUR ASPIRATION


To become the most valued partner to our clinical development and life sciences clients and a role model to the industry



Mission

OUR WORK

A Centre of Excellence in Clinical Development and Life Sciences



CLIENT FOCUS

Attentive,
responsive attitude

ACCOUNTABLE


Responsibility,
integrity and
ownership

RESPECT

Honest, transparent
and fair in our
communications

ENDURANCE

Perseverance and
belief in enduring
partnerships



An organization is as good
as the people who work in it.

Accordingly, our strength is primarily derived from our people. Our team is a collection of the brightest minds from various fields of study including medicine, biology, microbiology, genetics and pharmacology, selected for their passion, professionalism and commitment.

OUR WORK

Through our access to a wide network of tertiary-care hospitals around the country, we offer our valued partners an insight into a world of clinical trial in Sri Lanka'



Our Capabilities

FULLY GCP
COMPLIANT
ISO 9001:2015
CERTIFIED



A Regional Centre of Excellence in Clinical Development and Life Sciences



CLINICAL RESEARCH

One stop clinical research management solution provider in Sri Lanka



EMR SOLUTION PATIENT CARE APPLICATION

Representing Oneglance© in Sri Lanka as C|Glance



MONITORING AND CONSULTANCY

Medical writing, evaluation reports, monitoring services for research projects



PHARMACOVIGILANCE

Post-marketing studies



MEDICAL DEVICES

Introducing innovative medical devices in Sri Lankan Market



HEALTH APPLICATIONS

SmartHealth@ implementation in Sri Lanka



RWE STUDY CENTERS

Major 5 therapeutic areas



TELEMEDICINE

TeleClinic – Telemedicine platform

Our Services



REGULATORY
AFFAIRS



FEASIBILITY ASSESSMENT
AND INVESTIGATOR
SELECTION




HUMAN RESOURCE
MANAGEMENT



START-UP
ACTIVITIES



SITE SPACE
MANAGEMENT



PROJECT
MANAGEMENT



SUPPLY CHAIN
MANAGEMENT



PATIENT RECRUITMENT
AND RETENTION



SAFETY
REPORTING



MONITORING
AND REPORTING



COMPLIANCE
AND QUALITY
ASSURANCE




LOCAL VENDOR
MANAGEMENT'



The image features a complex molecular structure composed of dark blue spheres connected by thin rods, set against a light blue background with a fine grid pattern. The spheres vary in size, and the rods connect them in a non-linear, branching fashion. The overall aesthetic is clean, scientific, and modern.


CLINICAL
EXPERTISE

Clinical Trials




ONCOLOGY

STUDY	APPROVAL DURATION	TOTAL STARTUP DURATION	NO. OF SUBJECTS RANDOMIZED	% OF TARGET RANDOMIZATION	STUDY STATUS	AUDITS
Oral cavity cancer	20 weeks	32 weeks	80/ 150	N/A	Completed	CRO audits
Colorectal cancer	16 weeks	28 weeks	17/ 29	N/A	On-going	CRO audits
Metastatic breast cancer	12 weeks	20 weeks	06	100%	Completed	CRO and Sponsor audits



DIABETES & ENDOCRINOLOGY

STUDY	APPROVAL DURATION	TOTAL STARTUP DURATION	NO. OF SUBJECTS RANDOMIZED	% OF TARGET RANDOMIZATION	STUDY STATUS	AUDITS
Pediatric type 2 diabetes melitus	24 weeks	40 weeks	24/ 24	N/A	Completed	CRO and Sponsor audits
Diabetes mellitus and cardiovascular outcome	16 weeks	40 weeks	64	100%	Completed	CRO and Sponsor audits
Gestational diabetes	08 weeks	14 weeks	350/ 350	N/A	Completed	None



CARDIOLOGY

STUDY	APPROVAL DURATION	TOTAL STARTUP DURATION	NO. OF SUBJECTS RANDOMIZED	% OF TARGET RANDOMIZATION	STUDY STATUS	AUDITS
Community based blood pressure reduction	12 weeks	24 weeks	850/ 850	100%	Completed	None
Hypertension (GMRX)	16 weeks	22 weeks	0/ 350	N/A	On-going	CRO audits
Cardiovascular outcome (Odyssey)	16 weeks	32 weeks	314	100%	Completed	CRO and Sponsor audits
Hypertension (TRIUMPH)	12 weeks	22 weeks	700/ 700	N/A	Completed	CRO and Sponsor audits



AUTOIMMUNE DISEASE

STUDY	APPROVAL DURATION	TOTAL STARTUP DURATION	NO. OF SUBJECTS RANDOMIZED	% OF TARGET RANDOMIZATION	STUDY STATUS	AUDITS
IgA Nephropathy	16 weeks	28 weeks	30 - APR	N/A	Ongoing	CRO audits
Systemic lupus	18 weeks	34 weeks	02	60%	Completed	CRO audits
Lupus Nephritis	20 weeks	30 weeks	11	90%	Completed	CRO and Sponsor audits
Rheumatoid arthritis	18 weeks	30 weeks	24	80%	Completed	CRO and Sponsor audits



INFECTIOUS DISEASE

STUDY	APPROVAL DURATION	TOTAL STARTUP DURATION	NO. OF SUBJECTS RANDOMIZED	% OF TARGET RANDOMIZATION	STUDY STATUS	AUDITS
Dengue vaccine	54 weeks	72 weeks	2100/ 2100	100%	Ongoing	CRO and Sponsor audits
COVID Vaccine	Ongoing				Ongoing	None
COVID Nasal spray	Ongoing				Ongoing	None
Adenoviral conjunctivitis	16 weeks	24 weeks	48	100%	Completed	CRO and Sponsor audits



NEUROLOGY

STUDY	APPROVAL DURATION	TOTAL STARTUP DURATION	NO. OF SUBJECTS RANDOMIZED	% OF TARGET RANDOMIZATION	STUDY STATUS	AUDIT
Stroke (TRIDENT)	16 weeks	20 weeks	560/ 600	NA	Ongoing	CRO audits
Stroke-Non- Interventional (INTERACT)	16 weeks	22 weeks	110/ 300	NA	Ongoing	CRO audits
Bi lateral benign blepharospasm	14 weeks	24 weeks	33	100%	Completed	CRO audits
Head positioning (HEADPost)	06 weeks	12 weeks	272	100%	Completed	CRO audits

PSYCHIATRY

STUDY	APPROVAL DURATION	TOTAL STARTUP DURATION	NO. OF SUBJECTS RANDOMIZED	% OF TARGET RANDOMIZATION	STUDY STATUS	AUDITS
Schizophrenia	28 weeks	40 weeks	30 JUL	N/A	Ongoing	CRO and Sponsor audits

GASTROENTEROLOGY

STUDY	APPROVAL DURATION	TOTAL STARTUP DURATION	NO. OF SUBJECTS RANDOMIZED	% OF TARGET RANDOMIZATION	STUDY STATUS	AUDITS
Crohn's Disease	16 weeks	30 weeks	20 OCT	N/A	Ongoing	CRO audits
Ulcerative colitis	12 weeks	22 weeks	48	48%	Completed	CRO audits

SURGERY

STUDY	APPROVAL DURATION	TOTAL STARTUP DURATION	NO. OF SUBJECTS RANDOMIZED	% OF TARGET RANDOMIZATION	STUDY STATUS	AUDIT
Knee replacement	16 weeks	28 weeks	26	26	Completed	CRO audits

Words from our Collaborators

“

Sri Lanka was one of the top performing countries in ODYSSEY Outcomes in May.

Thank you for your efforts to help achieve this. Your commitment to the study is recognized and appreciated. Please share our thanks and congratulations with the investigators and study coordinators in your country.

**PROFESSOR PHILIPPE GABRIEL STEG &
PROFESSOR GREGORY G. SCHWARTZ**
Duke University

“

Sri Lanka has hit their country target of 2,100 subjects last Saturday. On behalf of Takeda Vaccines, we would like to congratulate you and your team for reaching your target this early. This is a big achievement, your country is the second globally to reach their target. Thank you very much for all the efforts put into this!

DR. YANEE & DEBBIE
Medical Monitors
Takeda Pharmaceuticals

“

Congratulations to this amazing team for their outstanding performance! Your hard work and persistence is greatly appreciated. Above all, your patient centric approach and commitment to quality and ethics is exemplary. I wish you all the very best. Keep up the good work.

MUBARAK NAQVI,
Senior Director,
Medical & Regulatory Affairs
Sanofi

“

I am finally back home; i.e. in the office, after the meeting in Hamburg – Germany where I went directly from Colombo. I am still under a big impression of all I saw and experienced in Sri Lanka and I am looking forward to work together with all of you - RO colleagues on this and other studies in the future. I am sure that together we can achieve a lot of success.

BRANKA DUVNJAK
Head of site management
Ergomed

“

This is a historical day for all of us. Thanks for all your guidance and support in making this happen. I know this is possible through a wonderful team work. Please convey my heartfelt thanks to all. I look forward to your continued support as we move ahead in this journey.

ANIRBAN ROY CHOWDHURY
Senior Director
Global Clinical Trial Operations MSD
Pharmaceuticals

“

I fall short of words, I cannot emphasize how much I enjoyed working with you, my experience of this association of 2.5+ years! RemediumOne has planted a seed of clinical research in Sri Lanka few years back, you all have watered it, its growing rapidly and would soon be a gigantic tree in the near future.

SACHIN S MANGALVEDHEKAR
Senior Manager
Clinical Project Management
Siro Clinpharm

RemediumOne
FOR LIFE

41/10, Guildford Crescent, Colombo 07

T: +941 12665266

F: +941 12665300

W: www.remediumone.com